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EDITORIAL
Platelet-derived growth factor: A new clinical target on
the horizon
At first glance, inflammation in general and growth 1.1 mesangioproliferative nephritis in rats [2]. A more
factors in particular represent an extremely complex, if potent PDGF antagonist, a specific DNA-aptamer, was
not chaotic, ensemble and clinicians are often confused also highly effective in reducing mesangial proliferation
by an ever-growing list of factors and a wealth of data and matrix accumulation in this model [3]. More impor-
on their biological activities. Given the redundancy of tant, a few days of treatment with this latter antagonist
many growth factor actions and the myriad of their mu- during the mesangioproliferative phase of a chronic anti-
tual interactions, it has come as somewhat of a surprise Thy 1.1 model completely prevented the subsequent de-
that specific antagonism of single cytokines is not only velopment of renal failure and glomerular as well as
possible but also highly effective in clinical situations. tubulointerstitial scarring [4]. This study by Ostendorf
The best example so far is the impressive effect of tumor et al thereby provided the first evidence of the long-held
necrosis factor-a (TNF-a) blockade in patients with belief that specific reduction of mesangial cell prolifera-
rheumatoid arthritis or inflammatory bowel disease. tion in vivo is indeed a meaningful therapeutic approach
Over the last years considerable evidence has been to mesangioproliferative disease [4].
gathered to implicate platelet-derived growth factor The major disadvantages of the abc PDGF-B antago-
(PDGF) in the pathogenesis of renal disease [reviewed nists are the need for parenteral application, the cost of
in 1]. In the molecule, two chains, PDGF-A and PDGF-B, producing them, and, in the case of neutralizing antibod-
form the biologically active homo- or heterodimers (very ies, their immunogenicity. Given the slowly progressive
recently, novel PDGF-C and PDGF-D chains have been nature of most human mesangioproliferative diseases,
cloned but nothing is known on their renal actions). In prolonged treatment is usually necessary and would be
the glomerulus, the PDGF-B chain, either as part of greatly facilitated if PDGF-B antagonists were easy to
PDGF-BB or PDGF-AB, is the most active molecule. produce and could be taken orally. Unfortunately, to
PDGF-B is produced within the glomerulus, released date, only a few oral anti-PDGF agents are available.
by infiltrating cells, overexpressed in many glomerular Trapidil, originally marketed as an antiplatelet agent,
diseases, and in vitro potently increases proliferation and also inhibits the binding of PDGF to its receptor [5]
matrix synthesis in mesangial cells. In vivo, administra- and results in a moderate reduction of glomerular cell
tion of PDGF-BB or the glomerular transfection with proliferation in the anti-Thy 1.1 nephritis model [6].
PDGF-B cDNA results in mesangioproliferative changes Whether this is the result of its antiplatelet or anti-PDGF
without other renal pathology. The most convincing evi- activity presently remains unknown. More recently, tyro-
dence for a crucial and nonredundant role of PDGF-B sine kinase blockers have been developed, which more
in mesangial biology is derived from mice genetically or less specifically impair the ability of the PDGF recep-
deficient in PDGF-B or its receptor, which after birth tor to signal through its intracellular tyrosine kinase do-
quickly die of renal abnormalities. The notable abnor- main. Again, using the anti-Thy 1.1 model, an inhibitor
mality is in the glomeruli, which contain normal glomeru- (KI 6896) that can be taken orally and prevents autophos-
lar endothelial and epithelial cells and a normal base- phorylation of both the PDGF receptor b-chain and the
ment membrane, but completely lack a mesangium.
basic fibroblast growth factor (bFGF) receptor, has been
Given the above, antagonism of PDGF-B in glomeru-
shown to reduce glomerular cell proliferation but not
lar disease has become the focus of several studies. Ex-
matrix accumulation in vivo [7]. This study now has been
periments with a neutralizing antibody against PDGF
extended by Gilbert et al, who, in this issue of Kidney
confirmed that it can acutely decrease mesangial cell
International [8], report their experience with a tyrosine
proliferation and matrix accumulation in the anti-Thy
kinase inhibitor (STI 571, formerly referred to as No-
vartis compound CGP 57148) that blocks the PDGF
receptor, the nonreceptor tyrosine kinase Abl, as wellKey words: platelet-derived growth factors, glomerular disease, mesan-
gial cell proliferation, anti-Thy 1.1 nephritis. as the c-kit receptor, the latter of which is expressed, for
example, on hematopoetic stem cells [9]. Gilbert et alÓ 2001 by the International Society of Nephrology
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provide convincing evidence that STI 571, administered candidate for our future therapeutic repertoire to com-
bat glomerular disease in humans.intraperitoneally from day 1 to 6 after induction of anti-
Thy 1.1 nephritis, can lead to a highly significant reduc-
Ju¨rgen Floege and Tammo Ostendorftion of mesangial cell activation and proliferation as well Aachen, Germany
as glomerular accumulation of extracellular matrix [8].
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renal interstitial damage [1]. However, in the only study
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